quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·745d
PRRelease
Syneos Health Inc. logo

Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)

SYNH· Syneos Health Inc.
Health Care
Original source

Companies

  • SYNH
    Syneos Health Inc.
    Health Care

Recent analyst ratings

  • Feb 13UpdateJP Morgan$28.00
  • Jan 17UpdateBarclays$25.00
  • Jan 13UpdateBarclays$25.00
  • Dec 14UpdateMizuho$38.00
  • Nov 7UpdateEvercore ISI$27.00
  • Oct 18UpdateJP Morgan$53.00

Related

  • PR724d
    Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
  • PR741d
    Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
  • PR786d
    NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
  • SEC926d
    SEC Form 15-12G filed by Syneos Health Inc.
  • NEWS933d
    Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe
  • SEC933d
    SEC Form 8-K filed by Syneos Health Inc.
  • INSIDER938d
    Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)
  • INSIDER938d
    Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022